ASCO 2025

De-escalating therapy - a step forward

Practice changing results for EBC patients?

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

WSG: HER2+ pooled analysis

HRD and BRCA status as a new innovative staging system?

TRADE: Abemaciclib in eBC

Intraoperative dose escalation helps to reach targeted dose of abemaciclib

ctDNA for the early detection of molecular recurrence

SG + Pembro in aTNBC: a new standard of care?

Next-gen endocrine therapies and ADCs: Updates from EMBER-3 and DB-06

Triple therapy 1st line | double therapy 2nd line - new treatment options for HR+ breast cancer patients

New compounds - new approaches: TNBC | HR+ | HER2+

A new standard for the firstline treatment of HER2+ patients?

A new standard for endocrine-resistant HR+ MBC?

AI and ADCs: Precision diagnostics & safer rechallenge in HER2+ breast cancer

Future new SOC for PD-L1-positive mTNBC

Re-exposition and ILD

New AKT/PIK3 Antagonist for treatment of mBC after CDK4/6 inhibitor treatment

Additional ADC effective for untreated TNBC

Effective ADC for HER2+ mBC with brain metastases

Sac-TMT for metastatic TNBC

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered pathway in patients with HER2-/ER+ BC

Vepdegestrant for treatment of ER+/HER2- aBC

ASCENT-04

Liquid biopsy as a navigator for personalized therapy guidance

Final OS-Analysis of INAVO-120 trial

A new first-line therapy for TNBC

T-DXd: Detecting ILD and treat again

Additional chemo-free option for TNBC

SG + Pembrolizumab might become SOC for PD-L1-positive advanced TNBC

ABC for metastatic TNBC

New SOC in first-line treatment for primary endocrine resistance

New treatment option in first line of metastatic TNBC

New firstline SOC for HER2+ metastatic BC

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.

Ipatasertib + Fulvestrant mejora la supervivencia libre de progresión en la vía alterada de PIK3CA en pacientes con cáncer de mama HER2 negativo y receptores de estrógeno positivos.

Nuova opzione di trattamento in prima linea per il TNBC metastatico

Vepdegestrant per il trattamento di ER+/HER2- aBC

Nuovo antagonista di AKT/PIK3 per il trattamento della mBC dopo il trattamento con inibitori CDK4/6

Analisi finale della OS dello studio INAVO-120

SG + Pembrolizumab podría convertirse en el tratamiento estándar para el TNBC avanzado con PD-L1 positivo.

Una nuova terapia di prima linea per il TNBC

Un nouveau traitement de première ligne pour le TNBC

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

PARP-inhibitor combinations in advanced prostate cancer

A bright future? Radioligands, hormonal treatment options and bispecific T-cell engagers

Immuntherapy - an evolution?

Localized CSPC - innovations

mHSPC - prognostification - indications on integration?

Stereotactic beam radiation therapy 2.0

Real world data from ironman registry confirms prognostic values for PSA

Adding EZH2 to Enzalutamide to decrease the development of antiandrogen resistance

mHSPC - ADT + NHT updates

New way of treatment for PCa

News of ANZUP trial

MMAI Model identifies patients who benfit from ARPI in STAMPEDE

Combination of LU-PSMA and immunotherapy, EVOLUTION trial

Rebirth of Rucaparib

Artera MMAI score en prediktiv biomarkör i STAMPEDE M0 studien

Real-world data från Ironman: PSA nivå en viktig prognostisk markör

Evolution: Kombination av LuPSMA och immunterapi.

ICI Combos in 1L and Maintenance – Mixed Bags or Meaningful Moves?

Complete but Not Finished: EV+P cCR Data Extend the SOC Case

ctDNA Clearance Confirms Added Value of Perioperative Durvalumab in MIBC

Sasanlimab + BCG: Practice-Changing Potential for Aggressive NMIBC

Update on EV-PEM in the EV-302 study

mUC EVP + subsequent therapies

CREST Study: Promising Results with PD-1 Inhibitor Sasanlimab in High-Risk BCG-Unresponsive NMIBC

NIAGARA study and circulating tumor DNA

The role of sansalimab (+ SG) in BCG-naive and BCG-refractory MIBC

A new prognostic factor in bladder cancer?: The case of ctDNA

New nectin-4 ADCs are coming

mUC - new approaches?

New option for high-risk NMIBC

Response matters in advanced urothelial cancer patients treated with EV-Pembro

Intensive caution of BCG Therapy

UTUC - enlighted

Benefit of IO/IO therapy in mUC

ASCO 2025 - Highlights for Bladder Cancer

El rol de sansalimab (+ SG) en el carcinoma urotelial muscularmente invasivo en pacientes naïve y refractarios al tratamiento con BCG.

HIF alfa sigue siendo una diana interesante en el RCC y otras enfermedades causadas por VHL

De nouveaux ADC pour la nectine-4 arrivent

ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου κύστης

La respuesta es importante en pacientes con cáncer urotelial avanzado tratados con EV-Pembro

¿Un nuevo factor pronóstico en el cáncer de vejiga? El caso del ctDNA

Long-term outcome of Nnivo-Ipi in clear cell RCC

Nivo + Ipi - Update & Insights

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line mRCC

5-Year OS data from the KEYNOTE-564 study

First lession

HIF alpha still an interesting target in RCC and other VHL driven diseases

Allogeneic CD70 CAR T Cells in refractory RCC

Neoadjuvant Approaches in resectable NSCLC: Insights from CheckMate 816 and NeoADAURA

New synergies? Radiotherapy and IO in Limited-Stage SCLC and Unresectable Stage III NSCLC

Neoadjuvant Alectinib in resectable stage III NSCLC

Updates in perioperative strategies in NSCLC

ctDNA stratification

Chemoimmunotherapy followed by chemoradiotherapy

CM-816: The OS results are positive and demonstrate that chemo-IO should be administered prior to surgery

Neadjuvant targeted therapy

MRD-analysis of the AEGEAN-trial

cTDNA in periop chemo-IO strategies

CheckMate 816: Update on OS-benefit

Actualizaciones en estrategias perioperatorias en NSCLC

CheckMate 816 : Mise à jour sur les avantages du système d'exploitation

CM-816 : Les résultats de l'OS sont positifs et démontrent que la chemo-IO doit être administrée avant l'intervention chirurgicale

New options in First-Line Therapy in metastatic NSCLC

Targeting rare mutations in metastatic NSCLC - HER2 and EGFR Exon 20

What is the future in the field of EGFR resistance?

HER3-DXd: dissapointing negative trial

Does the timing of IO-infusion impact survival?

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved outcome?

ADC in the 3L beats docetaxel

Is there still a place for HER3-DXd in advanced NSCLC?

Sevarbertinib – an additional option for HER2 exon 20 alterations

Benefit of IO is depending on the time of day of administration

Time of day of immunotherapy is important

Immunotherapy – before or after 3 p.m.?

Have we MET our target?

ADC as 3L in EGFR

HERTHENA-Lung02 unfortunately negative study - withdrawal of licence application

RELA-104-biomarker-analysis

TROP2 targets – where is first-line development heading?

KRAS G12C: Can immunotherapy improve patient outcome alone?

Updates on ADCs in EGFR resistance

HERTHENA-Lung02 étude malheureusement négative - retrait de la demande d'autorisation

KRAS G12C: Kan immunotherapie alleen het resultaat voor de patiënt verbeteren?

Hebben we ons doel gehaald?

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

Actualizaciones sobre los ADC en la resistencia al EGFR

Redefining SCLC: Lubri/Atezo maintenance in 1L, Tarlatamab as new SOC in 2L, and a new trispecific T-cell Engager

Taralatamb - the new SOC in 2L treatment

New therapies to improve patient survival

New maintenance therapy for SCLC

The first positive maintenance therapy in SCLC

Tarlatamab - a new SOC in second line

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

DeLLphi-304 : Changement radical dans le traitement de deuxième ligne du cancer du SCLC

De nouvelles thérapies pour améliorer la survie des patients

Exercise - The new old wonderdrug

LA HNSCC - New neoadjuvant SOC